Sex hormones and breast cancer risk and prognosis

Breast

Volumn 22, Issue S2, 2013, Pages

  Folkerd, Elizabeth ^a   Dowsett, Mitch ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Prognosis; Risk; Sex hormones

Indexed keywords

ALBUMIN; ANDROGEN; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 3A; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTRONE; ESTRONE SULFATE; PROGESTERONE RECEPTOR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE;

ALBUMIN BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CYP19 GENE; CYTOCHROME P450 3A GENE; DRUG EFFICACY; ESR1 GENE; ESTRADIOL BLOOD LEVEL; GENE; GENE CLUSTER; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GREB1 GENE; HISTONE METHYLATION; HORMONE ACTION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; PDZK1 GENE; PGR GENE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX HORMONE DETERMINATION; SHBG GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE BLOOD LEVEL; TFF1 GENE;

BREAST CANCER; PROGNOSIS; RISK; SEX HORMONES;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; MAMMARY GLANDS, HUMAN; MASTECTOMY; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884715444     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.007     Document Type: Article

References (57)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 148:162-165.
2. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., et al. Overview ofthe main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.
3. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. JNatl Cancer Inst 2005, 97:1652-1662.
4. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006, 295:2727-2926.
5. Simpson E.R., Mahendroo M.S., Means G.D., Kilgore M.W., Corbin C.J., Mendelson C.R. Tissue-specific promotors regulate aromatase cytochrome P450 expression. JSteroid Biochem Mol Biol 1993, 44:321-330.
6. Hankinson S.E., Manson J.E., Spiegelman D., Willett W.C., Longcope C., Speizer F.E. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3 year period. Cancer Epidemiol Biomarkers Prev 1995, 4:649-654.
7. Labrie F., Luu-The V., Bélanger A., Lin S.X., Simard J., Pelletier G., et al. Is dehydroepiandrosterone a hormone?. JEndocrinol 2005, 187:169-196.
8. Lønning P.E., Haynes B.P., Straume A.H., Dunbier A., Helle H., Knappskog S., et al. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin Cancer Res 2011, 17:4948-4958.
9. Lønning P.E., Haynes B.P., Straume A.H., Dunbier A., Helle H., Knappskog S., et al. Recent data on intratumor estrogens in breast cancer. Steroids 2011, 76:786-791.
10. Lønning P.E., Helle H., Duong N.K., Ekse D., Aas T., Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. JSteroid Biochem Mol Biol 2009, 117:31-41.
11. Haynes B.P., Straume A.H., Geisler J., et al. Intratumoral estrogen disposition in breast cancer. Clin Cancer Res 2010, 16:1790-1801.
12. The Endogenous Hormones and Breast Cancer Collaborative Group Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. JNatl Cancer Inst 2002, 94:606-616.
13. Zhang X., Tworoger S.S., Eliassen A.H., Hankinson S.E. Post menopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 2013, [Epub ahead of print].
14. Eliassen A.H., Missmer S.A., Tworoger S.S., Spiegelman D., Barbieri R.L., Dowsett M., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. JNatl Cancer Inst 2006, 98:1406-1415.
15. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into cancer and nutrition (EPIC). JNatl Cancer Inst 2005, 97:755-765.
16. Kendall A., Folkerd E.J., Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. JSteroid Biochem Mol Biol 2007, 103:99-109.
17. Collaborative group on hormonal factors in breast cancer Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001, 358:1389-1399.
18. Stone J., Folkerd E., Doody D., Schroen C., Treloar S.A., Giles G.G., et al. Familial correlations in postmenopausal serum concentrations of sex steroid hormones and other mitogens: a twins and sisters study. JClin Endocrinol Metab 2009, 94:4793-4800.
19. Peto J., Mack T.M. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000, 26:411-414.
20. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. NEngl J Med 2000, 343:78-85.
21. Dunning A.M., Dowsett M., Healey C.S., Tee L., Luben R.N., Folkerd E., et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. JNatl Cancer Inst 2004, 96:936-945.
22. Prescott J., Thompson D.J., Kraft P., Chanock S.J., Audley T., Brown J., et al. Genome-wide association study of circulating estradiol, testosterone and sex hormone binding globulin in postmenopausal women. PLoS One 2012, 7:e37815.
23. Coviello A.D., Haring R., Wellons M., Vaidya D., Lehtimäki T., Keildson S., et al. Agenome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple lociimplicated in sex steroid hormone regulation. PLoS Genet 2012, 8:e1002805.
24. Johnson N., Walker K., Gibson L.J., Orr N., Folkerd E., Haynes B., et al. CYP3A variation, premenopausal estrone levels, and breast cancer risk. JNCI 2012, 657-669.
25. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. JNatl Cancer Inst 2003, 95:1218-1226.
26. Bergström A., Pisani P., Tenet V., Wolk A., Adami H.O. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001, 91:421-430.
27. Ewertz M., Jensen M.-B., Gunnarsdóttir K.Á., Højris I., Jakobsen E.H., Neilsen D., et al. Effect of obesity on prognosis after early-stage breast cancer. JClin Oncol 2011, 29:25-31.
28. Protani M., Coory M., Martin J.H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010, 123:627-635.
29. Kwan M.L., Chen W.Y., Kroenke C.H., Weltzien E.K., Beasley J.M., Nechuta S.J., et al. Pre-diagnosis body mass index and survival after breast cancer in the after breast cancer pooling project. Breast Cancer Res Treat 2012, 132:729-739.
30. Pfeiler G., Königsberg R., Fesl C., Mlineritsch B., Stoeger H., Singer C.F., et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. JClin Oncol 2011, 18:2653-2659.
31. Sestak I., Distler W., Forbes J.F., Dowsett M., Howell A., Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. JClin Oncol 2010, 21:3411-3415.
32. Wakeling A.E., Valcaccia B. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. JEndocrinol 1983, 99:455-464.
33. Geisler J., Haynes B., Anker G., Dowsett M., Lønning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized cross-over study. JClin Oncol 2002, 20:751-757.
34. Geisler J., King N., Anker G., Ornati G., Di Salle E., Lønning P.E., et al. Invivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Chem Res 1998, 4:2089-2093.
35. Folkerd E.J., Dixon J.M., Renshaw L., A'Hern R., Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. JClin Oncol 2012, 30:2977-2980.
36. Pal B., Bouras T., Shi W., Vaillant F., Sheridan J.M., Fu N., et al. Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep 2013, http://dx.doi.org/10.1016/j.celrep.2012.12.020.
37. Dunbier A.K., Anderson H., Ghazoui Z., Folkerd E.J., A'Hern R., Crowder R.J., et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. JClin Oncol 2010, 28:1161-1167.
38. Haakensen V.D., Bjøro T., Lüders T., Riis M., Bukholm I.K., Kristensen V.N., et al. Serum estradiol levels associated withspecific gene expression patterns in normal breast tissue and in breast carcinomas. BMC Cancer 2011, 11:332.
39. Kristensen V.N., Sörlie T., Geisler J., Yoshimura N., Linegjærde O.-C., Glad I., et al. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. JSteroid Biochem Mol Biol 2005, 95:105-111.
40. Haynes B.P., Viale G., Galimberti V., Rotmensz N., Gibelli B., A'Hern R., et al. Expression of key estrogen-regulated genes differs substantially across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2013, 138:157-165.
41. Lønning P.E., Helle S.I., Johannessen D.C., Ekse D., Adlercreutz H. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996, 39:335-341.
42. Johnson S.R., Saccani-Jotti G., Smith I.E., Salter J., Newby J., Coppen M., et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338.
43. Martin L.A., Farmer I., Johnson S.R., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathway operate during the adaptation of MCF-7 cells to long term estrogen deprivation. JBiol Chem 2003, 278:30458-30468.
44. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev; 15: 1159-69.
45. Maskarinec G., Pagano I.S., Little M.A., Conroy S.M., Park S.-Y., Kolonel L.N. Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort. Breast Cancer Res 2013, 15:R7.
46. Walker K., Fletcher O., Johnson N., Coupland B., McCormack V.A., Folkerd E., et al. Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 2009, 69:6490-6499.
47. Greendale G.A., Palla S.L., Ursin G., Laughlin G.A., Crandall C., Pike M.C., et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the postmenopausal estrogen/progestin interventions mammographic density study. Am J Epidemiol 2005, 162:826-834.
48. Warren R., Skinner J., Sala E., Denton E., Dowsett M., Folkerd E., et al. Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006, 15:1502-1508.
49. McCormack V.A., Dowsett M., Folkerd E., Johnson N., Palles C., Coupland B., et al. Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 2009, 11:R38.
50. ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
51. Breast International Group (BIG) 1-98 Collaborative Group Acomparison of letrozole and tamoxifen therapy in postmenopausal women with primary breast cancer. NEngl J Med 2004, 350:1081-1092.
52. Smith I.E., Dowsett M., Yap Y.-S., Walsh G., Lönning P.E., Santen R.J., et al. Adjuvant aromatase inhibitors for early breast cancer after chemothapy-induced amenorrhoea: caution and suggested guidelines. JClin Oncol 2006, 24:2444-2447.
53. Torino F., Barnabei A., De Vecchis L., Appetecchia M., Strigari L., Corsello S.M. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. Endocr Relat Cancer 2012, 19:R21-R33.
54. Kendall A., Dowsett M., Folkerd E., Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006, 17:584-587.
55. Dowsett M., Folkerd E. Deficits in plasma oestradiol measurements in studies and management of breast cancer. Brest Cancer Res 2004, 7:1-4.
56. Lee J.S., Ettinger B., Stanczyk F.Z., VittInghoff E., Hanes V., Cauley J.A., et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. JClin Endocrinol Metab 2006, 91:3791-3797.
57. Stanczyk F.Z., Lee J.S., Santen R.J. Standardization of steroid hormone assays:why, how and when?. Cancer Epidemiol Biomarkers Prev 2007, 16:1713-1719.